Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients

We studied the effects of continuous subcutaneous infusion of octreotide (100 μg/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C-pepti...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 1997-11, Vol.38 (2), p.81-89
Main Authors: Lunetta, M, Di Mauro, M, Le Moli, R, Nicoletti, F
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - therapeutic use
Biological and medical sciences
C-Peptide - drug effects
C-Peptide - metabolism
Counterregulatory hormones
Diabetes Mellitus - drug therapy
Diabetes Mellitus - metabolism
Diabetes Mellitus, Type 1 - drug therapy
Diabetes Mellitus, Type 1 - metabolism
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Female
General and cellular metabolism. Vitamins
Glucose - metabolism
Hepatic glucose production
Hormones - blood
Hormones - metabolism
Humans
Hyperglycemia - drug therapy
Hypoglycemic Agents - therapeutic use
Injections, Subcutaneous
Insulin - therapeutic use
Liver - metabolism
Male
Medical sciences
Middle Aged
Octreotide
Octreotide - administration & dosage
Octreotide - therapeutic use
Pharmacology. Drug treatments
Type 1 diabetes
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We studied the effects of continuous subcutaneous infusion of octreotide (100 μg/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C-peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values ( P
ISSN:0168-8227
1872-8227
DOI:10.1016/S0168-8227(97)00094-6